[1]邓 奕,谢灿明,李方芳,等.从“血水同治”论治甲状腺相关性眼病[J].陕西中医,2024,(12):1666-1669.[doi:DOI:10.3969/j.issn.1000-7369.2024.12.017]
 DENG Yi,XIE Canming,LI Fangfang,et al.Treatment of thyroid-associated ophthalmopathy from “treating both blood and water”[J].,2024,(12):1666-1669.[doi:DOI:10.3969/j.issn.1000-7369.2024.12.017]
点击复制

从“血水同治”论治甲状腺相关性眼病
分享到:

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年12期
页码:
1666-1669
栏目:
学术探讨
出版日期:
2024-12-05

文章信息/Info

Title:
Treatment of thyroid-associated ophthalmopathy from “treating both blood and water”
作者:
邓 奕12谢灿明12李方芳12黄 群12姚小磊12
(1.湖南中医药大学第一附属医院,湖南 长沙 410007; 2.湖南中医药大学,湖南 长沙 410208)
Author(s):
DENG YiXIE CanmingLI FangfangHUANG QunYAO Xiaolei
(The First Hospital of Hunan University of Chinese Medicine,Changsha 410007,China)
关键词:
甲状腺相关性眼病 Graves病 血水同治 血水互结 痰瘀互结 活血利水法
Keywords:
Thyroid-associated ophthalmopathy Graves disease Treating both blood and water Blood water interaction Phlegm and blood stasis intertwined Method of promoting blood circulation and diuresis
分类号:
R 581
DOI:
DOI:10.3969/j.issn.1000-7369.2024.12.017
文献标志码:
A
摘要:
甲状腺相关性眼病(TAO)是一种自身免疫性疾病,中医学将其归入“鹘眼凝睛”范畴,认为其发生与痰湿阻滞、血脉瘀滞密切相关。活血利水法是彭清华教授治疗眼底疾病的常用治法,笔者发现其法在治疗眼眶疾病上同样疗效甚佳。血水在生理上同源,在病理上共病,其病理产物痰湿与血瘀恰与TAO的致病因素相拟合。故基于“血水同治”理论,分阶段探讨眼病“痰瘀互结”的病机特点,并提出“调理气机”对治疗痰瘀互结型TAO的重要性,为其辨证论治提供新思路、新方向。
Abstract:
Thyroid-associated ophthalmopathy(TAO)is an autoimmune disease,which is classified as “eye-catching” in traditional Chinese medicine,and it is considered that its occurrence is closely related to phlegm-dampness block and blood stasis.Ophthalmology method of promoting blood circulation and promoting diuresis is a commonly used treatment for fundus diseases by professor Peng Qinghua.The author found that it is equally effective in treating orbital diseases.Blood and water are physiologically homologous and pathologically co-morbid,and its pathological products,phlegm-dampness and blood stasis,are just consistent with the pathogenic factors of TAO.Therefore,based on the theory of “treating both blood and water”,this paper discusses the pathogenesis characteristics of “phlegm and blood stasis” of eye diseases in stages,and puts forward the importance of “regulating Qi-flow” in treating TAO,providing new ideas and new directions for its syndrome differentiation and treatment.

参考文献/References:

[1] LAZARUS J H.Epidemiology of Graves' orbitopathy(GO)and relationship with thyroid disease[J].Best Pract Res Clin Endocrinol Metab,2012,26(3):273-279.
[2] 郭清华,薛鹏,郑淑君,等.血清高半胱氨酸蛋白61、干扰素-γ、基质金属蛋白酶-9水平与Graves眼病活动性关系研究[J].陕西医学杂志,2024,53(6):810-813.
[3] 石晶琳.甲状腺相关眼病常见中医证候及证候要素的现代文献研究[J].中医文献杂志,2017,35(3):19-22.
[4] 李江伟,彭清华,吕怡,等.岐黄学者彭清华基于“血水同治”辨治视网膜静脉阻塞的经验[J].湖南中医药大学学报,2023,43(11):1997-2001.
[5] 方晗语,梁雨晴,梁超,等.从血水同源论损伤不必“专从血论”[J].教育教学论坛,2018,10(14):109-110.
[6] 李铎,李佳,刘悦,等.基于中医基础理论探讨痰证现代生物学基础[J].辽宁中医杂志,2020,47(2):93-95.
[7] 吴慧玲,周智媛,盛雪霏,等.郝小波教授基于“血水同治”理论运用活血利水方治疗葡萄膜炎黄斑水肿的经验[J].广西中医药大学学报,2021,24(2):44-46.
[8] 白海霞,刘晓清,吴权龙,等.基于血水同治理论探讨增殖性玻璃体视网膜病变的治疗[J].陕西中医,2023,44(9):1252-1254,1258.
[9] 赵盼,钟缘,彭清华.基于血水同治理论探讨渗出性老年性黄斑变性的治疗[J].湖南中医药大学学报,2024,44(5):853-856.
[10] 吴辰逸.《血证论》中关于血水同病的理论探讨及应用[D].南昌:江西中医药大学,2023.
[11] 吴虎强,王振华,刘晓云,等.活血化瘀疗法在眼科临床中的应用[J].科学技术创新,2017,21(23):50-51.
[12] 杨九天.刘喜明教授从痰湿论治甲状腺相关性眼病临床分析[D].北京:北京中医药大学,2022.
[13] 乡晓岚,彭宇婷,关晓莹,等.从中医学“六郁”探讨甲状腺相关性眼病活动期的病因病机和防治[J].中国中医眼科杂志,2023,33(11):1055-1059.
[14] 王婷,余江毅.Graves眼病的“虚-瘀-毒”病机层次探讨[J].实用中医内科杂志,2022,36(2):132-134.
[15] 朱明悦,邵迎新.导师从痰瘀论治甲状腺相关眼病经验[J].云南中医中药杂志,2023,44(4):117-119.
[16] 董伟伟,吴彩兰.甲状腺功能亢进症与血栓形成相关性研究进展[J].陕西医学杂志,2021,50(2):251-253,257.
[17] 侯江淇,徐世杰.血水互结证与当归芍药散的应用探析肺[J].中国中医基础医学杂志,2016,22(5):710-711.
[18] 张颢龄,张广德.张广德教授辨治Graves眼病经验撷要[J].世界中西医结合杂志,2019,14(10):1388-1391.
[19] 张艳,田晓玲,赵勇,等.基于五藏气血阴阳理论陈如泉常用瘿病“药对”体会[J].实用中医内科杂志,2020,34(12): 23-25.
[20] 张松松,陈霞波,贾梦娜.陈霞波分期辨治甲状腺相关眼病验案三则[J].中国乡村医药,2023,30(23):36-37,61.
[21] 蒋鹏飞,李书楠,刘培,等.益气养阴活血利水法在眼科疾病中的应用[J].中华中医药杂志,2021,36(12):7423-7425.
[22] 谢敏,赵勇,左新河.左新河教授治疗甲状腺相关性眼病经验[J].光明中医,2017,32(19):2767-2769.
[23] 陈怡鑫,陈艳奇,刘海鹏,等.基于国医大师张震疏调气机理论治疗自主高功能性甲状腺腺瘤验案举隅[J].云南中医中药杂志,2024,45(7):93-97.
[24] 宫秀丽,刘文红.“一气周流”理论临床应用[J].河南中医,2023,43(10):1487-1490.
[25] 袁晨,姜华,邢文文,等.活血化瘀方药调控水通道蛋白研究概况[J].陕西中医,2024,45(1):132-135.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82174443); 湖南省中医药防治眼耳鼻咽喉疾病与视功能保护工程技术研究中心项目(2018TP2008); 学科建设“揭榜挂帅”项目(22JBZ029); 中医药防治眼耳鼻咽喉疾病湖南省重点实验室项目(2017TP1018)
更新日期/Last Update: 2024-12-05